secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Oncology Therapeutics, Inc. (BBOT)
CIK:        0001869105
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001213900-25-018997
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Helix Acquisition Corp. II to merge with BridgeBio Oncology Therapeutics in $461M deal
--------------------------------------------------------------------------------

- Equity value of $461M; BBOT stockholders to receive shares of PubCo common stock.
- PIPE investments of ~$260M committed, including $75M from Cormorant; minimum $400M cash required at close.
- Closing expected after SEC effectiveness, shareholder approvals, and Nasdaq listing; drop-dead date Oct 31, 2025.
- Sponsor to forfeit shares if Helix Closing Cash < $400M; non-redemption agreements cover 450,900 Class A shares.
- Lock-up on Sponsor and existing Helix investors' shares for one year post-Closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1869105/000121390025018997/0001213900-25-018997-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1869105/000121390025018997/ea0232544-8k425_helix2.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-018997

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer